For patients with low-risk prostate cancer managed with active surveillance, obesity may increase risk of progression
the ONA take:
According to a new study published in the journal European Urology, researchers have found that obesity is linked with an increased risk of progression of low-risk prostate cancers in patients that are managed by active surveillance.
For the study, the researchers identified 565 men undergoing active surveillance for low-risk prostate cancer. The researchers found that during the median follow-up of 48 months, 168 men (30%) experienced pathologic progression and 172 men (30%) experienced therapeutic progression.
They did not find an association between obesity and risk of progression at the time of confirmatory biopsy, but beyond that, obesity was linked with an increased risk of pathologic progression (P = 0.007) and therapeutic progression (P = 0.007).
For every 5 unit increase in body mass index (BMI), the risk of pathologic progression increases (HR = 1.5, 95% CI: 1.1-2.1, P = 0.02). Similarly, the risk of therapeutic progression increases in the same manner (HR = 1.4, 95% CI: 1.0-1.9, P = 0.05).
Ultimately, the findings suggest that obesity is associated with a significantly elevated risk of prostate cancer progression after the confirmatory biopsy.
Obesity linked with increased risk of progression of low-risk prostate cancers in active surveillance.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|